Publication

Today's Mistakes and Tomorrow's Wisdom in Development and Use of Biomarkers for Barrett's Esophagus.

Journal Paper/Review - Feb 2, 2022

Units
PubMed
Doi
Contact

Citation
Frei N, Stachler M. Today's Mistakes and Tomorrow's Wisdom in Development and Use of Biomarkers for Barrett's Esophagus. Visc Med 2022; 38:173-181.
Type
Journal Paper/Review (English)
Journal
Visc Med 2022; 38
Publication Date
Feb 2, 2022
Issn Print
2297-4725
Pages
173-181
Brief description/objective

A histological diagnosis of dysplasia is our current best predictor of progression in Barrett's esophagus (BE), the precursor of esophageal adenocarcinoma (EAC). Despite periodic endoscopic surveillance and assessment of dysplastic changes, we fail to identify the majority of those who progress before the development of EAC, whereas the majority of patients undergo endoscopy without showing progression.